Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization.
OBJECTIVE
We evaluated the Macroflux microprojection array patch technology as a novel system for intracutaneous delivery of protein antigens.


METHODS
Macroflux microprojection array systems (330-microm micro-projection length, 190 microprojections/cm2, 1- and 2-cm2 area) were coated with a model protein antigen, ovalbumin (OVA), to produce a dry-film coating. After system application, microprojection penetration depth, OVA delivery, and comparative immune responses were evaluated in a hairless guinea pig model.


RESULTS
Macroflux microprojections penetrated into hairless guinea pig skin at an average depth of 100 microm with no projections deeper than 300 microm. Doses of I to 80 microg of OVA were delivered via 1- or 2-cm2 systems by varying the coating solution concentration and wearing time. Delivery rates were as high as 20 microg in 5 s. In a prime and boost dose immune response study, OVA-coated Macroflux was most comparable to equivalent doses injected intradermally. Higher antibody titers were observed when OVA was administered with the microprojection array or intradermally at low doses (1 and 5 microg). Macroflux administration at 1- and 5-microg doses gave immune responses up to 50-fold greater than that observed after the same subcutaneous or intramuscular dose. Dry coating an adjuvant, glucosaminyl muramyl dipeptide, with OVA on the Macroflux resulted in augmented antibody responses.


CONCLUSIONS
Macroflux skin patch technology provides rapid and reproducible intracutaneous administration of dry-coated antigen. The depth of skin penetration targets skin immune cells; the quantity of antigen delivered can be controlled by formulation, patch wearing time, and system size. This novel needle-free patch technology may ultimately have broad applications for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.
Matriano
James A
JA
Biological Sciences, ALZA Corporation, Mountain View, California 94043, USA. james.matriano@alza.com
Cormier
Michel
M
Johnson
Juanita
J
Young
Wendy A
WA
Buttery
Margaret
M
Nyam
Kofi
K
Daddona
Peter E
PE
D000279:Administration, Cutaneous; D000818:Animals; D000917:Antibody Formation; D000941:Antigens / Q000008:administration & dosage*; D004306:Dose-Response Relationship, Immunologic; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006168:Guinea Pigs; D007114:Immunization / Q000379:methods*; D008297:Male; D008845:Microinjections / Q000379:methods*; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology; D012867:Skin / Q000737:chemistry / Q000276:immunology
D000941:Antigens; D010047:Ovalbumin